|
T-cell dysfunctions in myelodysplastic syndromes |
Apr 2024 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
Oct 2024 |
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
|
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
Nov 2024 |
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
|
Targeting the Microenvironment in MDS: The Final Frontier |
Jul 2020 |
Frontiers in Pharmacology |
Myelodysplastic Syndromes (MDS) |
|
Targeting TP53 Mutations in Myelodysplastic Syndromes |
Apr 2020 |
Hematology/oncology clinics of North America |
Myelodysplastic Syndromes (MDS) |
|
TERC haploid cell reprogramming: a novel therapeutic strategy for aplastic anemia |
Jun 2023 |
Molecular Medicine |
Aplastic Anemia |
|
Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial |
Nov 2024 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
The case for upfront HLA-matched unrelated donor HCT as a curative option for adult acquired severe aplastic anemia: Upfront MUD HCT for adult severe aplastic anemia |
May 2019 |
Biology of Blood and Marrow Transplantation: Journal of the American Society of Blood and Marrow Transplantation |
Aplastic Anemia |
|
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes |
Jan 2019 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
The effect of hetrombopag combined with conventional treatment on immune function and quality of life in patients with severe aplastic anemia |
Sep 2024 |
Annals of Hematology |
Aplastic Anemia |
